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Background: Recovery of lost neurological function after stroke is limited and dependent on multiple mechanisms
including inflammatory processes. Selective pharmacological modulation of inflammation might be a promising
approach to improve stroke outcome.
Methods: We used 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (AMD3100), an antagonist to
the C-X-C chemokine receptor type 4 (CXCR4) and potential allosteric agonist to CXCR7, administered to mice twice daily
from day 2 after induction of photothrombosis (PT). In addition to functional outcome, the dynamics of post-stroke
microglia response were monitored in vivo by 2-photon-laser-microscopy in heterozygous transgenic CX3CR1-green
fluorescent protein (GFP) mice (CX3CR1
GFP/+) and complemented with analyses for fractalkine (FKN) and
pro-inflammatory cytokines.
Results: We found a significantly enhanced recovery and modified microglia activation without affecting infarct
size in mice treated with AMD3100 after PT. AMD3100 treatment significantly reduced the number of microglia in
the peri-infarct area accompanied by stabilization of soma size and ramified cell morphology. Within the ischemic
infarct core of AMD3100 treated wild-type mice we obtained significantly reduced levels of the endogenous
CX3CR1 ligand FKN and the pro-inflammatory cytokines interleukin (IL)-1β and IL-6. Interestingly, in CX3CR1-deficient
mice (homozygous transgenic CX3CR1-GFP mice) subjected to PT, the levels of FKN were significantly lower compared
to their wild-type littermates. Moreover, AMD3100 treatment did not induce any relevant changes of cytokine levels in
CX3CR1 deficient mice.
Conclusion: After AMD3100 treatment, attenuation of microglia activation contributes to enhanced recovery of lost
neurological function in experimental stroke possibly due to a depression of FKN levels in the brain. We further
hypothesize that this mechanism is dependent on a functional receptor CX3CR1.
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After ischemic stroke, the brain may regain lost neuro-
logical function to a limited extent by compensation and
relearning [1,2]. The definite outcome can be improved
by established rehabilitation regimes and might be en-
hanced by supportive pharmacological treatments.
Parallel and partially opposite processes contribute to
restoration of brain function after stroke. The interaction* Correspondence: karsten.ruscher@med.lu.se
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unless otherwise stated.of multiple mechanisms including neuronal plasticity,
astrogliosis, cell genesis, angiogenesis and inflammation
are important for the clinical development. Interestingly,
anti-inflammatory treatment significantly contributes to
functional recovery; examples are the specific blockade of
chemokines or pro-inflammatory molecules and their re-
ceptors. We have shown that modulation of the C-X-C
chemokine receptor type 4/C-X-C chemokine receptor
type 7 (CXCR4/CXCR7) pathway significantly improves
functional outcome and is associated with a reduction of
T-helper cells in the ischemic hemisphere [3]. Also,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gands [4] has been shown to improve recovery after
stroke.
Selective modulation of microglia function could be a
promising strategy that has been addressed in several ex-
perimental studies [5-7]. Recent investigations suggest
that the C-X-C chemokine ligand 12 (CXCL12)/CXCR4/
CXCR7 and the fractalkine (FKN)/CX3CR1 pathways are
instrumental in the regulation of microglia [8]. CXCL12
stimulates the release of FKN, a chemokine that, in the
brain, is mainly expressed by neurons [9,10] and exists
in a membrane-bound and a soluble form [11-13]. While
membranous FKN is involved in mechanisms of cell ad-
hesion, the soluble form acts as a chemoattractant [10].
The sole receptor for FKN is CX3C chemokine receptor
1 (CX3CR1) and is expressed on different immune cell
populations including microglia [9,14-16]. Initial studies
have demonstrated that the FKN/CX3CR1 pathway is
instrumental in chemotaxis of microglia [8,9], leukocyte
trafficking and microglia/macrophage recruitment [12].
In in vitro assays, FKN showed neuroprotective proper-
ties by activation of neuronal cell survival pathways
[17], and FKN also led to an increase of microglia sur-
vival [18].
After stroke, FKN expression increases in the necrotic
infarct core within the first hours followed by an upreg-
ulation in the peri-infarct area within the first week after
onset of the insult. CX3CR1-positive cells can be de-
tected in the ischemic tissue from 24 hours and are
strongly upregulated with a peak at day 7 after stroke
[12]. CX3CR1-deficient mice subjected to transient mid-
dle cerebral artery occlusion (MCAO) showed smaller
lesions compared to heterozygote and wild-type litter-
mates accompanied by reduced levels of pro-inflammatory
cytokines [19]. Results have been confirmed showing that
the administration of FKN to wild-type mice resulted in
smaller infarcts, but administration of FKN to FKN-
deficient mice resulted in bigger infarcts in a model of
permanent MCAO. Moreover, application of FKN to
microglia cell cultures resulted in reduced phagocytosis
[20]. Summarizing these findings, administration of
FKN but also CX3CR1 deficiency seems to be beneficial
in the acute phase after stroke. However, the role of
this pathway during the first weeks after stroke has not
been investigated.
Based on our previous studies demonstrating that antag-
onism of CXCR4 by 1,1′-[1,4-phenylenebis(methylene)]
bis[1,4,8,11-tetraazacyclotetradecane] (AMD3100) en-
hanced functional recovery after experimental stroke
[3] we hypothesized that specific CXCR4 antagonism
could be a therapeutic target to affect the FKN/
CX3CR1 pathway and to modulate microglia function
after stroke, to finally improve long-term outcome after
permanent focal ischemia.Methods
Experimental design
The microglial response and recovery of neurological
function were observed in parallel until 14 days after
ischemic stroke (Figure 1). Neurological function was
assessed in wild-type male C57BL/6 N-mice (28 to 35 g,
aged 12 to 16 weeks, purchased from Charles River,
Sulzfeld, Germany) using a newly assembled neuroscore
with a maximum score of 22 points (Table 1) consisting
of paw placement, whisker-reflex and tail suspension, as
well as a combination of the foot-fault test [21] and the
ladder-rung test [22]. The animals were trained at least
three times in climbing the ladder before recording the
neurological status prior to stroke. Animals were ex-
cluded from the study if the full score was not achieved
before photothrombosis (PT) (neuroscore <22 points) or
if only insufficient neurological deficits were observed at
day 1 after PT (neuroscore >11 points). Permanent cere-
bral ischemia was induced by PT. Mice were treated
with either AMD3100 or saline vehicle (vh) from day 2
to day 14, administered intraperitoneally twice daily
(every 12 hours, 0.5 mg/kg body weight). Neurological
deficits were assessed on days 1, 2, 7 and 14. Mice were
randomized (every other animal was allocated to the
same treatment group) and the studies were performed in a
blinded fashion to the investigator who performed surgeries
and behavioral tests. Microglial response was monitored
in vivo by 2-photon-laser-microscopy (2PLSM) through a
thinned skull-window before stroke, and at days 3, 7 and 14
(Figure 1). On day 14, animals were sacrificed and endpoint
analysis was carried out by immunohistochemistry.
All animal experiments were approved by the Malmö/
Lund ethical committee. Animals were housed in a con-
trolled environment with a 12:12 hour light cycle begin-
ning at 07:00 with room temperature maintained at 22°C
and with ad libitum access to food and water. For sur-
gery and 2PLSM the animals were anesthetized by in-
halation of isoflurane (isoflurane in N2O/O2 - 0.3:0.7,
4% for induction, 1.8% for maintenance) and local
anesthesia (bupivacain 0.25 mg/ml). During anesthesia,
the body temperature was monitored by a rectal thermis-
tor probe (Linton Instrumentation, Norfolk, UK) con-
nected to a heating pad maintaining body temperature at
36.7°C.
Animals
For behavioral analysis, 60 male C57BL/6 mice (28 to
35 g, aged 12 to 16 weeks; Charles River, Sulzfeld,
Germany) were purchased. Five out of 60 animals died
and nine animals had to be excluded from the study (see
below for exclusion criteria). From the 46 remaining ani-
mals, 13 mice were treated with AMD3100 after PT
(PT/AMD3100), 14 mice were treated with saline after
PT (PT/vh), 9 mice were treated with AMD3100 after
Figure 1 Experimental design. Assessment of neurological function was performed before (pre), and at day (d)1, 2, 7 and 14 following experimental
stroke induced by photothrombosis (PT) (study I); 2-photon-laser-microscopy (2PLSM) was performed before and on days 3, 7 and 14 after PT (study II).
One group of animals was treated with AMD3100 (0.5 mg/kg, twice daily), and control animals received intraperitoneal saline injections for the same
time (vehicle (VH) twice daily). At the endpoint of the study (day 14), animals were sacrificed and brains processed for endpoint analyses. Fractalkine
and cytokine levels were determined in CX3CR1 wild-type, heterozygote and knockout mice, respectively, on day 6 after PT (study III).
Table 1 Composite neuroscore for quantification of neurological deficits before and after photothrombotic stroke at
days 1, 2, 7 and 14
Test Score and description
Left forelimb flexion in suspension 0 - impaired paw is not moving and tightly held to the trunk
1 - impaired paw mostly held to the trunk, slightly movable
2 - impaired paw moves up and down, asymmetry to other paw
3 - slight asymmetry between the paws, both paws well movable
4 - normal, symmetric
Paw placement of the left side 0 - paw totally immobilized, hanging down, no movement
1 - paw hanging, but little movement back and forth (horizontal plane)
2 - paw hanging, horizontal and vertical movement below table level
3 - paw hanging horizontal and vertical movement up to table surface level
4 - paw hanging, mobile in all directions, reaching the table surface
5 - normal, paw is immediately taken up to the table surface
Whisker-reflex, left side 0 - not present
2 - present
Faults of the left forelimb walking 27 steps on a grid, 46.5 cm long,
step size 2 mm, interspace 1.5 cm (2–3 training sessions)
0 - 6 faults or more
1 - 5 faults
2 - 4 faults
3 - 3 faults
4 - 2 faults
5 - 1 fault
6 - no fault step
Before photothrombosis, the animal should achieve 22 points, at day 1 < 11 points, otherwise the animal was excluded from the study.
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Figure 2 Illustration of 2-photon-laser-microscopy image
(2PLSM) analysis. In the cartoon to the left the red circle represents
the photothrombotic stroke, and the green square the thinned
skull-window, through which green fluorescent protein (GFP)-CX3CR1
+
cells were imaged. Close to the infarct we defined region A, representing
the peri-infarct zone. The opposite side of the cranial window was
defined as region B.
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treated with saline after sham surgery (sham/vh).
To visualize microglia in vivo, 30 male transgenic C57/
Bl6 mice that carried GFP under the control of the
CX3CR1 promotor underwent 2PLSM (aged 30 to
40 weeks, weighing 25 to 35 g, own breeding; breeding
pairs were purchased from The Jackson Laboratory;
B6.129P(Cg)-Ptprca Cx3cr1tm1Litt/LittJ) [23]. To ensure
the presence of CX3CR1 and to visualize microglia we
only used mice heterozygous for CX3CR1 (CX3CR1
GFP/+).
It is of note that in addition to brain resident microglia
other immune cells express CX3CR1 and, therefore, are
positive for GFP. Hence, based on previous studies it can
be assumed that the majority of cells are microglia investi-
gated in the ischemic territory after PT [24,25]. Four out
of these 30 mice had to be excluded due to traumatic in-
jury or lethal anesthesia. The remaining 26 mice were ran-
domized into the following treatment groups: PT/
AMD3100, n = 10; PT/vh, n = 8; sham/AMD3100, n = 4;
and sham/vh, n = 4. Three AMD3100-treated and one
vehicle-treated animal could not be imaged on day 3, but
were imaged at the time points before PT, and day 7 and
day 14 after PT.
For protein analysis by Western blot, wild-type (n = 10),
CX3CR1
GFP/+ (n = 10) and CX3CR1
GFP/GFP mice (n = 10)
were subjected to PT and treated with AMD3100 (0.5 mg/kg
twice daily) or vehicle for 5 days starting on day 2 after
stroke. On day 6 after PT, FKN levels were determined in
the infarct core. Tissue from these animals was also used for
analysis of cytokine levels.
Photothrombosis
PT was carried out as described previously [26,27].
Briefly, anesthetized animals were placed into a stereo-
tactic frame. After shaving, a sagittal skin incision was
made on the scalp, subcutaneous connective tissue was
removed and the skullbone was dried. Five minutes
after intraperitoneal injection of the photosensitizer dye
Rose Bengal (0.1 mL at 10 mg/mL; Sigma-Aldrich,
Taufkirchen, Germany; Lot#MKBH0535V, the right
hemisphere was illuminated with a cold light source
(Schott KL 1500 LCD, intensity: 3050 K/4D) through a
round aperture measuring 2.5 mm in diameter (equal
to an illumination area of 4.909 mm2) for 20 minutes
(coordinates related to Bregma: +1.5 mm lateral and +0.5
anterior). Thereafter, the scalp incision was sutured and
the mice were transferred to their home cage to recover.
For 2PLSM, PT was induced in CX3CR1
GFP/+ trans-
genic mice. The lesion was located rostral and adjacent
to the thinned skull window (for details see below) at
the approximate coordinates of 1.5 mm lateral and 0.5
anterior related to bregma. CX3CR1
GFP/+ transgenic ani-
mals were illuminated at a light intensity of 3050 K/4E
for 15 minutes through a 1.5 mm round aperture (equalto an illumination area of 1.767 mm2). Among the
CX3CR1
GFP/+ animals undergoing 2PLSM, 2 out of 10
AMD3100 treated (PT/AMD3100) animals and four out
of eight vehicle-treated animals (PT/vh) received PT
under the conditions 2.5 mm/3050 K/4D/20 minutes.
Compared to the parameters in mice with a lesion size
of 1.5 mm these PT settings did not affect values for
soma size and cell number in the specific region of
interest.
2-Photon-laser-microscopy
2PLSM was performed in accordance with Yang and col-
legues [27]. Briefly, after placing the anesthetized animal
onto a custom-made plate, a sagittal skin incision from
eye to ear level was made and all connective tissue was
removed from the skull to attach a custom-made blade
to the dry bone (3 M Vetbond-glue, No. 1469SB) so that
the head of the animal could be firmly adjusted to a
skull-holder on the plate [27]. Using a dental drill and
microsurgical blades a thinned window measuring ap-
proximately 1.5 × 1.5 mm with a remaining bone thick-
ness of about 20 μm was prepared. The animal was then
transferred to the microscope stage and a drop of MilliQ
water was placed onto the skull window. After
optimization of imaging conditions, 2PLSM imaging was
performed in Z-stack planes of 424.9 × 424.9 μm (x/y/z,
0.83 μm/pixel, unless stated otherwise) down to a sub-
dural depth of 75 to 150 μm by a multiphoton Zeiss
LSM 7MP upright laser scanning microscope using a
W-Plan Apochromat 20_/1.0 DIC Vis-IR water immersion
objective (×20, Carl Zeiss, Jena, Germany) controlled by
ZEN 2010 imaging software (Carl Zeiss) (Figure 2). GFP
was excited by a Mai Tai DeepSee Ti:Sapphire pulsed laser
(Spectra-Physics, Irvine, CA, USA) tuned to 875 nm [28].
Further computerized analysis followed ex vivo with Ima-
geJ (1.43u, NIH, Washington, USA) and Adobe Photoshop
(CS5 extended 12.04x64, Adobe, USA).
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(CX3CR1
+) in the entire area under the thinned skull
window and defined a region “A” located adjacent to the
infarct core and a region “B” most distant from the in-
farct core (Figure 2). Microglia were counted and their
soma sizes determined at Otsu-threshold [29,30] within
regions of interest represented by z-stacks measuring
424.9 × 424.9 × 75 μm (x/y/z) located in either A or B.
To eliminate microglia activation caused by any experi-
mental procedures (for example, preparing the skull win-
dow or laser stimulation) respective results obtained in
sham-operated mice were subtracted from those found
in mice subjected to PT. In addition, we defined a value
“C” represented by the equation C(dx) = (A(dx) −A
(pre)) − (B(dx) − B(pre)) where the increase in number in
cells from before infarct induction (pre) to a day x (dx)
in region B was subtracted from the respective value in
region A. By combined use of sham corrections and this
algorithm we gained precise information about the
stroke-induced changes in number of microglial cells.
Infarct size measurement
Brains from perfusion-fixed animals were cut into cor-
onal sections with a thickness of 30 μm and stained for
neuronal nuclei (NeuN; procedure described in the im-
munohistochemistry paragraph). The noninjured portion
of the ipsilateral and contralateral hemisphere were
encircled and the indirect infarct volume was calculated
by integration of areas from serial sections (1 mm) of
each brain as described previously [31].
Immunohistochemistry
Brain sections (30 μm in thickness) were rinsed in
phosphate-buffered saline (PBS). Endogenous peroxidase
activity was quenched by washing the sections in a solution
of PBS with 3% H2O2 and 10% methanol for 15 minutes.
After subsequent rinsing in PBS, blocking was achieved by
incubation in a solution containing 5% normal donkey
serum (NDS) in 0.25% Triton X-100 in PBS (Tx/PBS) for
1 hour. Thereafter, sections were incubated with a mouse
anti-neuronal Nuclei (NeuN) antibody (diluted at 1:1000,
Merck Millipore, Billerica, MA, USA) or a rabbit anti-
CXCR4 antibody (diluted at 1:200; Abcam, Cambridge,
UK) at 4°C in 5% NDS in Tx/PBS overnight. The next
day, sections were rinsed in 1% NDS in Tx/PBS
followed by incubation with respective biotinylated sec-
ondary antibodies in 2% NDS in Tx/PBS at room
temperature for 90 minutes. Sections were washed with
Tx/PBS and incubated with avidin-biotin-complex
(ABC; Vector Laboratories, Burlingame, CA, USA) for
1 hour. Following this incubation, the sections were
rinsed in PBS. The ABC reaction was visualized using
NiDAB (Dabsafe, Saveen Werner AB, Limhamn,
Sweden) with the addition of NiCl2 and a mixture of3% H2O2 in H2O. Thereafter, sections were rinsed in
PBS, mounted on glass slides, dried overnight, dehy-
drated, treated with xylene and then cover-slipped with
Pertex (Histolab AB, Västra Frölunda, Sweden).
Immunofluorescence
Brain sections (thickness 30 μm) from 4% paraformaldehyde-
perfused animals were used. After blocking in 5% NDS
in Tx/PBS for 60 minutes, sections were incubated with
primary antibody in Tx/PBS in 5% NDS at 4°C over-
night. The following antibodies were used: rat anti-
cluster of differentiation 68 (CD68; diluted at 1:200;
AbD Serotec, Düsseldorf, Germany), rabbit anti-
CXCR4 (diluted at 1:200; Abcam), mouse anti-CD45
(diluted at 1:25; AbD Serotec) and rabbit anti-ionized
calcium binding adaptor molecule 1 (Iba1; diluted
1:2000; Wako Chemicals, Neuss, Germany). The next
day, the sections were rinsed with 1% NDS in Tx/PBS
three times for 10 minutes. All the following steps were
performed in the dark in order to preserve the fluoro-
phores conjugated to the secondary antibodies. Sec-
tions were incubated with secondary antibodies in 2%
NDS in Tx/PBS for 90 minutes at room temperature
and rinsed in PBS three times for 10 minutes. Finally,
the sections were rinsed in PBS and mounted on super-
charged glass slides, allowed to dry, cover-slipped using
PVA-DABCO and analyzed using LSM 510 confocal
microscopy (Carl Zeiss).
Western blotting
Proteins were extracted from brain tissue as described
earlier [32]. Proteins were separated on a 10% SDS poly-
acrylamide gel and were transferred onto polyvinyldi-
fluoride membranes. Unspecific protein binding sites
were blocked in blocking buffer containing 20 mM Tris,
136 mM NaCl, pH 7.6, 0.1% Tween 20 and 5% nonfat
dry milk. FKN was detected by a rabbit anti-FKN anti-
body (Torrey Pines Biolabs, Secaucus, NJ, USA; dilu-
tion 1:1000). After overnight incubation at 4°C, signals
were obtained by binding of a secondary anti-rabbit
horse radish peroxidase-linked antibody (1:50000;
Sigma-Aldrich, Deisenhofen, Germany) and visualized
by exposing the membrane to a charge-coupled device
camera (LAS1000, Fujifilm, Tokyo, Japan) using a
chemiluminescence kit (Merck Millipore, Billerica, MA,
USA). Membranes were stripped and reprobed for β-actin
(Sigma-Aldrich), and diluted 1:50,000. After densitometric
analysis using Image J software, FKN levels were calcu-
lated as a percentage of β-actin expression.
Measurement of cytokines
Tissue samples from the ischemic core were collected as
described previously [32]. Cytokine levels were measured
from brain tissue homogenates by a multiplex
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tions using a SECTOR Imager 6000 reader (Mesoscale,
Gaithersburg, MD, USA).
Statistical analysis
Statistical analysis was performed using Excel® (Micro-
soft Excel® for Mac 2011, 14.3.6) and SPSS-Statistics®
(IBM, Version21, IBM Svenska, Stockholm, Sweden).
Results from behavioral testings were evaluated by the
Mann–Whitney U-test (significance level 0.05, confi-
dence interval 0.95). Quantity of cells, soma sizes and
Western blot results were evaluated by Students t test
(significance level 0.05, confidence interval 0.95). Cyto-
kine levels were analyzed by one-way analysis of vari-
ance. Post-hoc multiple comparisons were performed as
stated in the figure legends and P < 0.05 was considered
significant.
Results
Treatment with AMD3100 improves functional outcome
after photothrombosis in mice without affecting infarct size
After permanent focal ischemia induced by PT in wild-
type C57BL/6 mice and treatment either with saline or
AMD3100, neurological function was assessed by a com-
posite neuroscore before and on day 1, 2, 7 and 14 afterFigure 3 Impact of AMD3100 treatment on functional recovery after ph
neuroscore in CX3CR1 wild-type mice before and on days 1, 2, 7 and 14 after p
PT/AMD3100, n = 13; PT/vehicle, n = 14; sham/AMD3100, n = 9; sham/vehicle, n
with saline or AMD3100 from day (d)7 to d14 and (B) from d1 to d14 after PT.
are indicated in the figure.PT (Table 1). We observed a significant improvement of
the neuroscore in AMD3100-treated mice compared to
vehicle-treated animals during the second week after
PT (vh 2.3%, AMD3100 18.2%, Mann–Whitney U-test
P = 0.004; Figure 3A). Over the whole observation
period of 14 days, AMD3100-treated animals finally re-
covered significantly better than vh-treated animals (vh
18.2%, AMD3100 27.3%, Mann–Whitney U-test P = 0.008;
Figure 3B). Treatment with AMD3100 did not affect be-
havior in sham-operated mice (data not shown). Import-
antly, analysis of infarct volumes did not show a
significant difference between the treatment groups
(vh, 5.35 ± 0.81; AMD3100, 5.56 ± 0.65; Student’s t test
P = 0.85; Figure 4A).
Treatment with AMD3100 reduces soma size and number of
microglia cells in CX3CR1
GFP/+ mice after photothrombosis
PT caused an intensive accumulation of GFP+ microglial
cells in CX3CR1
GFP/+ mice (Figure 4B). Treatment with
AMD3100 strongly attenuated this inflammatory re-
sponse in the ischemic territory. 2PLSM was carried out
to characterize the dynamics during activation of micro-
glial cells in the ischemic territory. We used heterozy-
gous CX3CR1
GFP/+ mice with one allele for GFP and one
functional CX3CR1 allele. To evaluate the stroke-otothrombosis. Neurological outcome was assessed by a composite
hotothrombosis (PT). The following numbers of animals were included:
= 10. (A) Percentage of improvement in outcome in mice treated either
Statistical analysis was performed by Mann–Whitney U-test, and differences
Figure 4 Effect of AMD3100 treatment on infarct size and accumulation of green fluorescent protein (GFP)-positive cells in the
ischemic territory. (A) Infarct volumes in mice treated with saline (n = 9) or AMD3100 (n = 9) displayed as means ± SEM on day 14 after
photothrombosis. Representative coronal sections of a vehicle- and AMD3100-treated animal are shown to the right. (B) Accumulation of GFP+
cells in the ischemic territory in a vehicle- and an AMD3100-treated CX3CR1
+/GFP mouse. Scale bars: 200 μm. The frame illustrates the area analyzed for
GFP+ cells by 2-photon-laser-microscopy.
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morphology of GFP+ cells accumulating in the peri-
infarct area (Figures 2 and 5A-D). By calculating cell
numbers within the defined regions A and B we found a
significantly lower number of GFP+ cells in the proximal
peri-infarct area of AMD3100- compared to vehicle-
treated animals at days 3, 7 and 14 after PT (Figure 5A-C).
Interestingly, this occurred already 1 day after initiating
AMD3100 treatment. No changes in the number of cells
have been observed within the treatment groups during
the observation period of 14 days. Hence, soma sizes were
significantly decreased from day 7 onwards in vehicle-
treated mice (Figure 5C).
In addition, we observed a clear morphological change
of the microglial cells in AMD3100-treated animals, in
particular during the early phase after stroke (Figure 5D).
At day 3, the microglial somas in vehicle-treated mice
more than doubled their size compared to baseline mea-
surements before stroke (increase of soma size: 119.4%)
(Figure 5C, D). Soma sizes of microglia in AMD3100-treated mice only increased by 13.2% (Figure 5C, D). At
later time points soma sizes were similar, there was no
significant difference in the increase of soma size detect-
able among the treatment groups. Together, our results
suggest that treatment with AMD3100 significantly
modifies activation of microglia in the peri-infarct area
after PT in mice within 24 hours after the first drug
administration.
Green fluorescent protein-positive cells in CX3CR1
GFP/+ mice
reveal microglia/macrophage-specific immunohistochemical
properties of phagocytosing cells
To further analyze the phenotype of CX3CR1
+ green
fluorescent cells in CX3CR1
GFP/+ mice, we performed
immunohistochemistry in the animals that had been
sacrificed after 2PLSM-experiments at d14 after stroke.
As shown in Figures 4B and 6, accumulation of GFP+
cells was observed in the infarct core and the peri-
infarct area. The majority of cells also were found posi-
tive for Iba1, a marker for activated microglia/
Figure 5 (See legend on next page.)
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Figure 5 Analysis of green fluorescent protein (GFP)-positive cells in the peri-infarct area by 2-photon-laser-microscopy (2PLSM).
(A) Representative 2PLSM-image stacks of GFP+ microglia measured in a volume of 424.9 × 424.9 × 75 μm (x/y/z) before photothrombosis (PT)
(pre) and in the peri-infarct area of a vehicle (d3-vh)- and an AMD3100 (d3-AMD)-treated mouse on day 3 after PT. Scale bars: 50 μm. (B) Images
displayed in (A) after threshold modification according to Otsu [30] in order to measure soma sizes. (C) Quantitative analysis of GFP+ cells and
their soma sizes in the peri-infarct area. Values are normalized to respective values of cell numbers and soma sizes before PT. Error bars represent
standard error of the mean. Statistical analysis was performed by Student’s t test (*P < 0.05, AMD3100 versus vehicle treatment at the same time
point; #P < 0.05, versus the same treatment at day 3). (D) Illustration of representative morphologies of GFP+ cells in a vehicle- and an AMD3100-
treated mouse, respectively, before (pre), and on days 3, 7 and 14 after PT. Scale bars: 10 μm.
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the infarct core was not homogenous, but mostly ap-
peared in a typical amoeboid morphology indicative for
phagocytosing cells. For further characterization, co-
stainings were performed with CD68, a marker for phago-
cytosis, and CD45, a marker for peripheral immune cells
infiltrating the ischemic territory (Figure 6). GFP+ cells
were positive for CD68 and CD45 in the infarct core and
adjacent peri-infarct area. Some of the cells co-expressed
CD68 and CD45. Together, our data show the accumula-
tion of microglia/macrophages in the ischemic territory.
We further assessed the expression of CXCR4 to find
out more about the target cells of AMD3100. In addition
to neocortical neurons, CXCR4-positive cells were de-
tected in the ischemic territory (Figure 7). Co-staining of
CXCR4 with GFP demonstrates their expression in
microglia/macrophages in this region supporting previ-
ous studies (Figure 7) [3]. These results illustrate that
the majority of GFP+ cells accumulating in and around
the infarct display microglia/macrophage properties and
that these cells might be susceptible for the treatment
with AMD3100.
Reduction of fractalkine levels depends on functional
CX3CR1 in the subacute post-stroke phase
FKN is the endogenous ligand for CX3CR1 and it has
been shown that activation of the CXCL12/CXCR4 path-
way induces the release of FKN by increased activity of
the protease ADAM10/17 [13]. To test if CXCR4 antag-
onism affects FKN after PT, wild-type (n = 8), heterozy-
gote (CX3CR1
GFP/+) (n = 8) and CX3CR1-deficient
(CX3CR1
GFP/GFP) mice (n = 8) were subjected to PT and
treated with AMD3100 (0.5 mg/kg twice daily) or ve-
hicle for a total of 5 days. On day 6 after PT, FKN levels
were determined in the infarct core by Western blotting.
Three specific bands have been identified (Figure 8).
While the 95 kDa band corresponds to the released sol-
uble form of FKN, the origin of the 55 kDa and 78 kDa
bands have not been unraveled yet. FKN levels found in
wild-type animals were decreased in animals treated
with AMD3100 compared to mice treated with vehicle.
In particular, soluble FKN (95 kDa FKN; vh, 3.51 ± 0.5;
AMD3100, 1.87 ± 0.14 arbitrary units (AU)) and the
55 kDa FKN (vh, 1.15 ± 0.22; AMD3100, 0.42 ± 0.04 AU)signal were significantly reduced in AMD3100-treated
animals (Figure 8A).
Interestingly, vehicle-treated CX3CR1-deficient mice
showed lower FKN levels compared to their wild-type
littermates, and treatment did not significantly affect the
levels of any of the three forms of FKN (Figure 8B). In
addition, the levels of FKN did not differ when compar-
ing mice of both genotypes treated with AMD3100 (data
not shown). CX3CR1
GFP/+ mice showed a less prominent
reduction compared to wild-type animals of the 78 kDa
FKN (vh, 2.03 ± 0.16; AMD3100, 1.37 ± 0.13 AU) and
the 95 kDa FKN form (vh, 1.92 ± 0.13; AMD3100, 1.45 ±
0.04 AU) while the 55 kDa form (vh, 1.91 ± 0.17;
AMD3100, 1.54 ± 0.05 AU) remained unaffected. These
results show that treatment with AMD3100 signifi-
cantly affects the release of FKN in the infarct core,
and that the release is dependent on a functional recep-
tor, CX3CR1.
Treatment with AMD3100 reduced the level of
pro-inflammatory cytokines in CX3CR1 wild-type mice
after photothrombosis
Levels of pro-inflammatory cytokines were measured in
order to study inflammation in the ischemic territory of
CX3CR1 wild-type and CX3CR1-deficient mice subjected
to PT. As shown in Figure 9, reduced levels of interleu-
kin (IL)-1β) and IL-6 were found in CX3CR1 wild-type
mice treated with AMD3100 (0.5 mg/kg) for a total of
5 days (study III) compared to vehicle-treated animals.
Interestingly, the levels of IL-12p70, interferon-gamma,
IL-2, CXCL1 and IL-5 were also lower in AMD3100-
treated mice (data not shown); however, differences did
not reach statistical significance. In contrast, treatment
with AMD3100 did not affect the levels of cytokines in
CX3CR1-deficient mice, whereas levels of IL-12p70 were
significantly increased compared to vehicle-treated mice
(Figure 9). Based on these experiments, we conclude that
a functional CX3CR1 receptor is essential to achieve anti-
inflammatory effects mediated by AMD3100 treatment.
Discussion
The present investigation demonstrates that treatment
with the CXCR4 antagonist AMD3100 in mice subjected
to permanent focal ischemia enhances long-term recovery
Figure 6 (See legend on next page.)
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Figure 6 Phenotype of green fluorescent protein (GFP)-positive cells in the ischemic territory. Upper panels: colocalization of CD68 (Cy3, red),
GFP (green, CX3CR1) and CD45 (white, Cy5) in the ischemic territory of a vehicle- and AMD3100-treated mouse after photothrombosis (PT).
Middle panels illustrates the expression of ionized calcium binding adaptor molecule 1 (Iba1) in CD68/GFP- and CD45/GFP-positive cells. Scale
bar: 50 μm. Lower panel: colocalization of GFP (green) with Iba1 (Cy3, red) in the ischemic core after PT. Scale bar: 10 μm.
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correlation between the improved outcome after stroke
and a reduced microglial response during the first 14 days.
Importantly, treatment did not interfere with the acute tis-
sue response involving cell death mechanisms and the
early activation of microglia observed during the first
hours after stroke. In addition, we provide the first in vivo
evidence that levels of FKN, the endogenous ligand for
CX3CR1, in the ischemic territory are affected by inhib-
ition of the CXCL12/CXCR4 pathway.
AMD3100 enhances recovery of lost neurological function
after photothrombosis
In line with previous investigations showing an im-
proved outcome after AMD3100 treatment in miceFigure 7 Phenotype of green fluorescent protein (GFP)-positive cells
ischemic territory 14 days after photothrombosis (PT). A higher magnificatio
right 50 μm. Lower panel: co-staining for CXCR4 (Cy5, red) and GFP (green
squared area is shown in the bottom panel. Scale bars: low magnification 5subjected to permanent MCAO [34] and rats subjected
to transient MCAO [3] we observed better neurological
scores in mice subjected to PT treated with AMD3100 for
a total of 12 days starting on day 2 after stroke. In contrast
to previous studies performed in rats, AMD3100 treat-
ment had no immediate effect on recovery. Differences
have not been observed until the second week after stroke
onset. This might be due to various mechanisms of recov-
ery dependent on the experimental model (permanent
versus transient model) and species, including specific
pharmacokinetics in mice and rats. In addition, several
studies have demonstrated that application of CXCL12
(stromal cell line derived factor 1, SDF1) exerts beneficial
effects on cellular repair mechanism recovery and, espe-
cially, the proliferation of neuronal progenitor cells andin the ischemic territory. Upper panel: expression of CXCR4 in the
n of the squared area is shown to the right. Scale bars: left 100 μm;
, CX3CR1) in the proximal peri-infarct area. Higher magnification of the
0 μm, high magnification 10 μm.
Figure 8 Effect of AMD3100 treatment on levels of fractalkine (FKN) after photothrombosis. (A) Levels of FKN in the infarct core of
wild-type (wt) and (B) CX3CR1-deficient (ko) mice treated either with AMD3100 (AMD) or vehicle (vh) for 5 days starting on day 2 after
photothrombosis. Specific bands for FKN and β-actin have been quantified, and ratios for the 55 kDa, 78 kDa and 95 kDa FKN are displayed as
means ± SEM. Statistical differences are indicated in the graphs and were performed by Student’s t test.
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CXCL12/CXCR4 signaling by AMD3100 downregulates
the migration of neuroblasts at the site of ischemic injury
4 weeks after stroke [37]. In these studies, however, func-
tional outcome after administration of the CXCR4 antag-
onist AMD3100 has not been assessed. We have shown
that administration of AMD3100 during the first days
after stroke conveys anti-inflammatory actions [3]. The
migration of neuronal progenitor cells from stem cell
niches towards the ischemic lesion is relevant for stroke
recovery; however, during the early period after stroke and
due to multiple ongoing processes, the inhibition of detri-
mental inflammatory processes prevails and is of prime
significance to regain function.
Microglia activation is downregulated by blockade of
CXCL12 actions
Our study supports the idea that downregulation of the
FKN/CX3CR1 pathway diminishes detrimental actions of
post-stroke inflammation. Similar results were observed in
the acute phase after transient MCAO showing thatFigure 9 Cytokine analysis in the infarct core after photothrombosis
infarct core of wild-type and CX3CR1-deficient mice treated either with AM
Five animals are included in each treatment group. Data are presented as m
in the figure (one-way analysis of variance, Fisher’s least significant differenCX3CR1 deficiency reduced ischemic damage and CX3CR1-
deficient mice displayed a stroke-protective inflammatory
milieu during the first 72 hours after stroke [19,38].
The interaction between microglia, neurons and other
surrounding cells after stroke is mainly accomplished by
molecular cues such as the release of danger-associated
molecule patterns and, more specifically, cytokines/che-
mokines [39]. Among others, the CXCL12/CXCR4 and
the FKN/CX3CR1 pathways have been implicated in the
activation of immune cells in the post-ischemic brain
[12,13,17]. Earlier studies demonstrated an involvement
of the FKN/CX3CR1 pathway in cell adhesion and che-
moattraction of monocytes but also microglia in vitro
[8,40]. In addition, it has been shown that the applica-
tion of FKN to microglia cultures reduces their phagocy-
totic activity [20]. It has therefore been suggested that
the activation of CX3CR1 by released FKN is involved in
the regulation of microglia to remain in a ramified
phenotype with potential neuroprotective properties
[20,41]. AMD3100 specifically blocks the actions of
CXCL12 and thus inhibits the neuronal and glial release(PT). Levels of the cytokines interleukin (IL)-12p70, IL-1β, and IL-6 in the
D3100 (0.5 mg/kg) or vehicle (saline) for 5 consecutive days after PT.
eans ± standard error of the mean. Statistical differences are indicated
ce test).
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tory response would be expected. According to our ob-
servations, however, this is not the case. Also others
demonstrated that AMD3100 attenuated the post-stroke
inflammatory response during the early phase after tran-
sient MCAO in mice and reduced brain edema, which
was accompanied by an improved functional outcome
[34]. A reduction of inflammation has also been ob-
served in a rat transient MCAO model when treatment
was initialized on day 2 after stroke onset [3]. In the
present study we observed a lower cell number, a
stabilization of morphology of microglia accompanied by
reduced levels of pro-inflammatory cytokines indicating
that AMD3100 treatment mitigates the post-stroke
stimulation of microglial cells. In AMD3100-treated
mice, microglia hardly showed any signs of swelling in
the early post-stroke phase, and microglia accumulation
or proliferation was reduced during the whole observa-
tion period of 14 days, possibly due to an initial inhib-
ition of phenotype transformation. Based on previous
studies, the majority of GFP-positive cells studied here
are microglia cells. However, cells cannot be distin-
guished from invading macrophages based on the pres-
entation of antigens.
Our results also indicate the necessity of a specific
time window to achieve beneficial effects by treatment
with AMD3100. To summarize, our data imply that both
pathways (CXCL12/CXCR4 and FKN/CX3CR1) specific-
ally impact on the activation of microglia and putative
intercellular crosstalks. Specifically, we demonstrated
that the blockade of CXCL12 actions at the CXCR4 re-
duced FKN levels, which could be responsible for the
observed attenuated microglia activation. It has also
been shown that AMD3100 acts as an allosteric agonist
on the receptor CXCR7 [43]. Based on our results, we
conclude that the effects at CXCR4 are not abrogated by
potential binding of AMD3100 to CXCR7. However, we
cannot exclude that AMD3100 bound to CXCR7 exerts
functions contributing to recovery of function after stroke.
Phenotype of GFP+ cells in the ischemic territory of
CX3CR1
GFP/+ mice
Investigation of the phenotype of GFP+ immune cells in
the ischemic territory showed that 14 days after induc-
tion of PT, GFP+/CD68+ microglia/macrophages accu-
mulated predominantly in the ischemic infarct core.
Only a small population of cells was positive for CD45,
indicating also the presence of blood-derived leukocytes.
Together with an amoeboid morphology these cells most
likely represented phagocytes. Co-localization of GFP+
cells with Iba1 further supports the idea that these cells
were in an activated state as demonstrated previously
[33]. Within the infarct core, micrographs also show
CD68+ cells lacking GFP. A conceivable explanation ofthis finding could be the existence of different CD68-
expressing immune cell populations that may downregu-
late the expression of GFP driven by the CX3CR1 pro-
motor. Further research is needed to explain this
phenomenon.
The expression of CXCR4 in the post-ischemic brain
confirms a target for AMD3100 treatment after ischemic
injury. CXCR4+ cells in the infarct core and adjacent
peri-infarct area displayed a round-shaped morphology
and have been identified as immune cells previously [3].
Other CXCR4+ cells observed throughout the brain
could be identified as neurons [3,44].
Relevance of fractalkine for immune cell activation and
inflammation after stroke
Several studies have examined the role of FKN after ex-
perimental stroke, with conflicting results. Here we dem-
onstrate a significant decrease of FKN levels in the
ischemic infarct core of wild-type mice treated with
AMD3100 for 5 days. Thus, antagonism of CXCR4 re-
duces the release of FKN after stroke, which confirms
earlier published data [13]. Importantly, immunofluores-
cence analysis showed CXCR4 expression on immune
cells and neuron-like cells in the post-ischemic brain indi-
cating that both cell types are susceptible for AMD3100
treatment and may release FKN.
In mice deficient for CX3CR1, FKN levels were lower
than those obtained in wild-type littermates. A possible
explanation might be a positive feedback loop between
glia and neurons regulating FKN shedding. Moreover,
treatment with AMD3100 did not affect the already re-
duced levels of FKN in CX3CR1-deficient mice subjected
to PT. We therefore propose that a functional receptor,
CX3CR1, is necessary for FKN modulation through
CXCR4 antagonism.
It also has been shown that in CX3CR1-deficient mice
there might be a lower production of pro-inflammatory
cytokines, leading to a protective inflammatory milieu in
stroke with smaller lesions [19,45]. However, one has to
consider that smaller infarct sizes per se may result in
lower levels of pro-inflammatory molecules. In the
present study we could not find any differences concern-
ing the levels of pro-inflammatory cytokines in the
infarct core after PT in wild-type compared to CX3CR1-
deficient mice. On the other hand, our results indicate
that anti-inflammatory effects caused by AMD3100
treatment require a functional CX3CR1 since the drug
was ineffective in deficient mice.
We demonstrate that reduced endogenous FKN levels
and reduced levels of pro-inflammatory cytokines are ac-
companied by an enhanced recovery of lost neurological
function. This is in contrast to studies showing that
FKN significantly reduced brain damage after permanent
focal ischemia [20]. Discrepancies might be explained by
Walter et al. Journal of Neuroinflammation  (2015) 12:24 Page 14 of 15differences in the study designs. While the present pro-
ject investigated the role of endogenous FKN, recombin-
ant FKN was administered to mice shortly before
induction of stroke in the previous study and infarct vol-
umes have been studied at an earlier time point after
stroke [20]. Nevertheless, it could be speculated that an
increase of FKN in the early phase after stroke has dif-
ferent effects on inflammatory cascades and cell death
mechanisms than at later stages. Acutely after stroke
there are more brain resident CX3CR1
+ microglial cells
present in the ischemic territory that are responsive to
FKN. Several days later, the tissue milieu in the ischemic
territory changes, with accumulation of different subsets
of CX3CR1-expressing immune cells [23,46].
Conclusion
Our study shows that treatment with the CXCR4 antag-
onist AMD3100 significantly enhanced long-term recov-
ery of lost neurological function after permanent focal
ischemia. Treatment with AMD3100 inhibited the acti-
vation of microglia in the proximal peri-infarct area
most likely due to reduced levels of FKN during the first
week after stroke. Results support the idea that specific
CXCR4 antagonism might be exploited in future ap-
proaches to improve rehabilitative treatment in stroke
patients.
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